Durvalumab plus FLOT improves survival in Asians with G/GEJ adenocarcinoma
a day ago
byElaine Soliven
Adding durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) improves event-free survival (EFS) and overall survival (OS) in Asian patients with resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to a subgroup analysis of the phase III MATTERHORN trial presented at ESMO Asia 2025.